Methylphenidate Alternatives Compared
Methylphenidate | Rexulti (brexpiprazole) | Bupropion |
|
---|
Methylphenidate | Rexulti (brexpiprazole) | Bupropion |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Methylphenidate can help improve symptoms of ADHD but may cause dependence and side effects include a headache, loss of appetite, and sleeplessness. It is recommended that methylphenidate should not... View more |
Prescription only
Rexulti is an atypical antipsychotic that may be used to treat adults with schizophrenia or depression, or used to relieve agitation associated with dementia in Alzheimer's disease. Most people... View more |
Prescription only
Bupropion may be used in the treatment of depression or as an aid to smoking cessation; however, side effects may include insomnia, neuropsychiatric adverse events, or seizures. It carries a black... View more |
Related suggestions |
|||||||||||||||||||||||
More about Methylphenidate | More about Rexulti (brexpiprazole) | More about Bupropion | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Methylphenidate has an average rating of 7.2 out of 10 from a total of 1082 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 17% reported a negative effect. |
Rexulti has an average rating of 6.6 out of 10 from a total of 490 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 26% reported a negative effect. |
Bupropion has an average rating of 7.0 out of 10 from a total of 2900 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Methylphenidate side effects |
View all Rexulti side effects |
View all Bupropion side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Methylphenidate prices |
View all Rexulti prices |
View all Bupropion prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Jornay PM, Metadate CD, Methylin, Methylin ER, QuilliChew ER, Quillivant XR, Relexxii, Ritalin, Ritalin LA View more |
N/A |
Aplenzin, Budeprion, Budeprion SR, Forfivo XL, Wellbutrin SR, Wellbutrin XL | ||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
4 hours |
91 hours |
30 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
High potential for abuse
Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 207 drugs are known to interact with Methylphenidate:
|
A total of 600 drugs are known to interact with Rexulti:
|
A total of 559 drugs are known to interact with Bupropion:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
December 05, 1955 |
July 10, 2015 |
December 30, 1985 |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
|
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.